

Gene Modifying Immunotherapy for Blood Cancer Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/G7E07022360FEN.html>

Date: February 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: G7E07022360FEN

Abstracts

Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells. It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells. This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient. CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.

This report contains market size and forecasts of Gene Modifying Immunotherapy for Blood Cancer in Global, including the following market information:

Global Gene Modifying Immunotherapy for Blood Cancer Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Gene Modifying Immunotherapy for Blood Cancer market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

CAR T-cell Therapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene Modifying Immunotherapy for Blood Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Type, 2021 (%)

CAR T-cell Therapy

TCR T-cell Therapy

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Application, 2021 (%)

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

B Cell Lymphoma

Multiple Myeloma

Other

Global Gene Modifying Immunotherapy for Blood Cancer Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Kite Pharma

Juno Therapeutics

Cellectis

Ziopharm Oncology

Celyad

Bluebird Bio

Bellicum Pharmaceuticals

Mustang Bio

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Gene Modifying Immunotherapy for Blood Cancer Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER OVERALL MARKET SIZE

- 2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size: 2021 VS 2028
- 2.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Gene Modifying Immunotherapy for Blood Cancer Players in Global Market
- 3.2 Top Global Gene Modifying Immunotherapy for Blood Cancer Companies Ranked by Revenue
- 3.3 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Companies
- 3.4 Top 3 and Top 5 Gene Modifying Immunotherapy for Blood Cancer Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Gene Modifying Immunotherapy for Blood Cancer Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Players in Global Market

3.6.1 List of Global Tier 1 Gene Modifying Immunotherapy for Blood Cancer Companies

3.6.2 List of Global Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Gene Modifying Immunotherapy for Blood Cancer Market Size Markets, 2021 & 2028

4.1.2 CAR T-cell Therapy

4.1.3 TCR T-cell Therapy

4.2 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts

4.2.1 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022

4.2.2 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028

4.2.3 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Market Size, 2021 & 2028

5.1.2 Acute Lymphocytic Leukemia

5.1.3 Chronic Lymphocytic Leukemia

5.1.4 B Cell Lymphoma

5.1.5 Multiple Myeloma

5.1.6 Other

5.2 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts

5.2.1 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022

5.2.2 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028

5.2.3 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Market Size, 2021 & 2028

6.2 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts

6.2.1 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022

6.2.2 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028

6.2.3 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028

6.3.2 US Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.3.3 Canada Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.3.4 Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028

6.4.2 Germany Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.3 France Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.4 U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.5 Italy Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.6 Russia Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.7 Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.4.8 Benelux Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028

6.5.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.5.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.5.4 South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size,
2017-2028

6.5.5 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size,
2017-2028

6.5.6 India Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
6.6 South America

6.6.1 By Country - South America Gene Modifying Immunotherapy for Blood Cancer
Revenue, 2017-2028

6.6.2 Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.6.3 Argentina Gene Modifying Immunotherapy for Blood Cancer Market Size,
2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood
Cancer Revenue, 2017-2028

6.7.2 Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size,
2017-2028

6.7.3 Israel Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

6.7.4 Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size,
2017-2028

6.7.5 UAE Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis

7.1.1 Novartis Corporate Summary

7.1.2 Novartis Business Overview

7.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Major Product
Offerings

7.1.4 Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue in Global
Market (2017-2022)

7.1.5 Novartis Key News

7.2 Kite Pharma

7.2.1 Kite Pharma Corporate Summary

7.2.2 Kite Pharma Business Overview

7.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Major Product
Offerings

7.2.4 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue in

Global Market (2017-2022)

7.2.5 Kite Pharma Key News

7.3 Juno Therapeutics

7.3.1 Juno Therapeutics Corporate Summary

7.3.2 Juno Therapeutics Business Overview

7.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Major

Product Offerings

7.3.4 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue in

Global Market (2017-2022)

7.3.5 Juno Therapeutics Key News

7.4 Collectis

7.4.1 Collectis Corporate Summary

7.4.2 Collectis Business Overview

7.4.3 Collectis Gene Modifying Immunotherapy for Blood Cancer Major Product

Offerings

7.4.4 Collectis Gene Modifying Immunotherapy for Blood Cancer Revenue in Global

Market (2017-2022)

7.4.5 Collectis Key News

7.5 Ziopharm Oncology

7.5.1 Ziopharm Oncology Corporate Summary

7.5.2 Ziopharm Oncology Business Overview

7.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Major

Product Offerings

7.5.4 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue

in Global Market (2017-2022)

7.5.5 Ziopharm Oncology Key News

7.6 Celyad

7.6.1 Celyad Corporate Summary

7.6.2 Celyad Business Overview

7.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Major Product

Offerings

7.6.4 Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue in Global

Market (2017-2022)

7.6.5 Celyad Key News

7.7 Bluebird Bio

7.7.1 Bluebird Bio Corporate Summary

7.7.2 Bluebird Bio Business Overview

7.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Major Product

Offerings

7.7.4 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)

7.7.5 Bluebird Bio Key News

7.8 Bellicum Pharmaceuticals

7.8.1 Bellicum Pharmaceuticals Corporate Summary

7.8.2 Bellicum Pharmaceuticals Business Overview

7.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings

7.8.4 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)

7.8.5 Bellicum Pharmaceuticals Key News

7.9 Mustang Bio

7.9.1 Mustang Bio Corporate Summary

7.9.2 Mustang Bio Business Overview

7.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings

7.9.4 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)

7.9.5 Mustang Bio Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Gene Modifying Immunotherapy for Blood Cancer Market Opportunities & Trends in Global Market

Table 2. Gene Modifying Immunotherapy for Blood Cancer Market Drivers in Global Market

Table 3. Gene Modifying Immunotherapy for Blood Cancer Market Restraints in Global Market

Table 4. Key Players of Gene Modifying Immunotherapy for Blood Cancer in Global Market

Table 5. Top Gene Modifying Immunotherapy for Blood Cancer Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Companies, 2017-2022

Table 8. Global Companies Gene Modifying Immunotherapy for Blood Cancer Product Type

Table 9. List of Global Tier 1 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Gene Modifying Immunotherapy for Blood Cancer

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Gene Modifying Immunotherapy for Blood Cancer

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Gene Modifying Immunotherapy for Blood Cancer

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Gene Modifying Immunotherapy for Blood Cancer

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue,
(US\$, Mn), 2017-2022

Table 25. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue,
(US\$, Mn), 2023-2028

Table 26. By Country - South America Gene Modifying Immunotherapy for Blood
Cancer Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Gene Modifying Immunotherapy for Blood
Cancer Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood
Cancer Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood
Cancer Revenue, (US\$, Mn), 2023-2028

Table 30. Novartis Corporate Summary

Table 31. Novartis Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 32. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$,
Mn), (2017-2022)

Table 33. Kite Pharma Corporate Summary

Table 34. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product
Offerings

Table 35. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue
(US\$, Mn), (2017-2022)

Table 36. Juno Therapeutics Corporate Summary

Table 37. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product
Offerings

Table 38. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer
Revenue (US\$, Mn), (2017-2022)

Table 39. Cellectis Corporate Summary

Table 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 41. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

Table 42. Ziopharm Oncology Corporate Summary

Table 43. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 44. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

Table 45. Celyad Corporate Summary

Table 46. Celyad Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 47. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

Table 48. Bluebird Bio Corporate Summary

Table 49. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 50. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

Table 51. Bellicum Pharmaceuticals Corporate Summary

Table 52. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 53. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

Table 54. Mustang Bio Corporate Summary

Table 55. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings

Table 56. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Gene Modifying Immunotherapy for Blood Cancer Segment by Type in 2021

Figure 2. Gene Modifying Immunotherapy for Blood Cancer Segment by Application in 2021

Figure 3. Global Gene Modifying Immunotherapy for Blood Cancer Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021

Figure 8. By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 9. By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 10. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 11. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 12. US Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 16. Germany Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 17. France Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn),

2017-2028

Figure 20. Russia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 24. China Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 28. India Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 30. Brazil Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

Figure 33. Turkey Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Gene Modifying Immunotherapy for Blood Cancer Revenue, (US\$, Mn), 2017-2028

Figure 37. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Gene Modifying Immunotherapy for Blood Cancer Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/G7E07022360FEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7E07022360FEN.html>